Quarterly report pursuant to Section 13 or 15(d)

Segment Information

v2.4.0.6
Segment Information
6 Months Ended
Dec. 31, 2012
Segment Information

G. Segment Information:

The Company has two reportable segments based on the nature of products (biotechnology and hematology). Following is financial information relating to the Company’s reportable segments (in thousands):

 

     Quarter Ended     Six Months Ended  
     December 31,     December 31,  
     2012     2011     2012     2011  

External sales

        

Biotechnology

   $ 69,628      $ 69,808      $ 139,131      $ 142,111   

Hematology

     5,455        4,854        10,977        10,147   
  

 

 

   

 

 

   

 

 

   

 

 

 

Consolidated net sales

   $ 75,083      $ 74,662      $ 150,108      $ 152,258   
  

 

 

   

 

 

   

 

 

   

 

 

 

Earnings before income taxes

        

Biotechnology

   $ 36,883      $ 37,878      $ 73,877      $ 77,862   

Hematology

     2,148        1,681        4,251        3,599   
  

 

 

   

 

 

   

 

 

   

 

 

 

Segment earnings before income taxes

     39,031        39,559        78,128        81,461   

Unallocated corporate expenses and equity method investee losses

     (1,585     (1,686     (2,696     (3,088
  

 

 

   

 

 

   

 

 

   

 

 

 

Consolidated earnings before income taxes

   $ 37,446      $ 37,873      $ 75,432      $ 78,373